CFO
STRO icon

Callan Family Office’s Sutro Biopharma STRO Stock Holding History

Callan Family Office’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,618
Closed -$11.5K – 942
2025
Q2 		$11.5K Buy
+1,618
New +$13.2K ﹤0.01% 928

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Callan Family Office's STRO Position: Q3 2025 in Review

Callan Family Office sold out of Sutro Biopharma (STRO) in Q3 2025, closing a stake of 1,618 shares — an estimated $11.5K sold.

Callan Family Office first reported a position in STRO in Q2 2025 and held it in 1 quarter. The position peaked at $11.5K in Q2 2025. 87 funds tracked by Wall St. Rank hold STRO as of Q3 2025.

  • Callan Family Office reported no remaining Sutro Biopharma position as of Q3 2025 after selling out during the quarter.
  • Callan Family Office sold 1,618 Sutro Biopharma shares in Q3 2025, an estimated $11.5K.
  • Callan Family Office first reported a position in Sutro Biopharma in Q2 2025 and held it in 1 quarter.
  • Callan Family Office's Sutro Biopharma position peaked at $11.5K in Q2 2025.
  • 87 funds tracked by Wall St. Rank held Sutro Biopharma as of Q3 2025.

Based on Callan Family Office's 13F filing for Q3 2025, filed 4 Nov 2025.